** Capricor Therapeutics' CAPR.O shares up 4.5% premarket at $26.55 after co capitalizes on its soaring stock by raising equity
** San Diego, California-based biotech early Fri sells 6 mln shares at $25 for $150 mln gross proceeds
** On Weds, CAPR shares surged 371% to an 8-year high after co said its experimental cell therapy, deramiocel, slowed the progression of Duchenne muscular dystrophy (DMD) in a late-stage trial
** On Thurs, shares fell ~15% to $25.40
** Co intends to use net offering proceeds for continued development and manufacturing of its product candidates, working capital and general purposes
** Piper Sandler and Oppenheimer are joint bookrunners
** CAPR has ~45.7 mln shares outstanding
** All 10 analysts rate CAPR "strong buy" or "buy"; median PT of $44 up from $21.50 a month ago, per LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Comments